Maplight Therapeutics, INC Form 4 insider transactions

James Woodruff Lillie, Chief Scientific Officer of MapLight Therapeutics, Inc., sold 22,082 shares of common stock on August 3, 2026 for $12.54 per share.

Catalyst4, Inc. reported changes in beneficial ownership of MapLight Therapeutics, Inc. common stock on July 28, 2026.

Troy Cox, a Director of MapLight Therapeutics, Inc., purchased 15,620 shares of common stock on July 28, 2026 for $9.52 per share.

Jonathan Gillis, CAO and Interim CFO of MapLight Therapeutics, Inc., sold 36,979 shares of common stock on July 15, 2026.

Anatol Kreitzer, Chief Discovery Officer of MapLight Therapeutics, Inc., sold 36,284 shares of common stock on July 15, 2026.

Christopher A. Kroeger, Chief Executive Officer and a Director of MapLight Therapeutics, Inc., sold 147,639 shares of common stock on July 15, 2026.

James Woodruff Lillie, Chief Scientific Officer of MapLight Therapeutics, Inc., sold 18,267 shares of common stock on July 15, 2026.

Kristopher Hanson, General Counsel of MapLight Therapeutics, Inc., sold 16,508 shares of common stock on July 15, 2026.

Erin Pennock Foff, Chief Medical Officer of MapLight Therapeutics, Inc., sold 47,158 shares of common stock on July 15, 2026.

Troy Cox, a director at MapLight Therapeutics, Inc., was granted restricted stock units and stock options on June 23, 2026, as part of the company's non-employee director compensation policy.

Martin Babler, a Director at MapLight Therapeutics, Inc., was granted restricted stock units and stock options on June 23, 2026.

Timothy John Garnett, a Director at MapLight Therapeutics, Inc., reported the acquisition of 3,932 restricted stock units and the grant of a stock option for 14,902 shares.

Nanna Liebach, a Director at MapLight Therapeutics, Inc., was granted restricted stock units and a stock option on June 23, 2026, as part of the company's non-employee director compensation policy.

George Pavlov, a Director at MapLight Therapeutics, Inc., acquired restricted stock units and a stock option, signaling continued commitment and potential future equity gains.

Maria C. Walker, a Director at MapLight Therapeutics, Inc., acquired restricted stock units and stock options on June 23, 2026, as part of the company's non-employee director compensation policy.

CEO Christopher Kroeger sold 118,235 shares of MapLight Therapeutics under a pre-arranged Rule 10b5-1 trading plan.

General Counsel Kristopher Hanson sold 13,917 shares of MapLight Therapeutics common stock via a pre-arranged 10b5-1 trading plan.

CEO Christopher A. Kroeger sold 68,861 shares of MapLight Therapeutics common stock via a pre-arranged 10b5-1 trading plan.

Chief Medical Officer Erin Pennock Foff sold 4,438 shares of MapLight Therapeutics common stock via a 10b5-1 trading plan.

Chief Scientific Officer James Woodruff sold 721 shares of MapLight Therapeutics common stock under a pre-arranged 10b5-1 trading plan.

MapLight Therapeutics CFO Vishwas Setia sold 36,371 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Chief Medical Officer Erin Foff sold 50,280 shares of MapLight Therapeutics common stock via a pre-arranged 10b5-1 trading plan.

Chief Scientific Officer James Woodruff sold 51,707 shares of MapLight Therapeutics common stock between May 4 and May 6, 2026, under a pre-arranged trading plan.

General Counsel Kristopher Hanson sold 13,917 shares of MapLight Therapeutics common stock via a Rule 10b5-1 trading plan.

MapLight Therapeutics CEO Christopher A. Kroeger sold 49,844 shares of common stock via a pre-arranged 10b5-1 trading plan.

Jonathan Gillis, CAAO and PAO of MapLight Therapeutics, Inc., reported the sale of company stock totaling over 120,000 shares between April 27-28, 2026, executed under a Rule 10b5-1 trading plan.

Anatol Kreitzer, Chief Discovery Officer at MapLight Therapeutics, sold a significant number of shares under a Rule 10b5-1 trading plan.

Chief Discovery Officer Anatol Kreitzer sold 3,316 shares of MapLight Therapeutics to cover tax obligations.

Jonathan Gillis, CAAO and PAO of MapLight Therapeutics, sold 3,590 shares to cover statutory tax withholding obligations.

General Counsel Kristopher Hanson sold 1,827 shares of MapLight Therapeutics to cover statutory tax withholding obligations.